Skip to main content

Table 2 Disease characteristics by age group

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

  Age < 70 years (N = 333) n (%) Age ≥ 70 years (N = 188) n (%) All patients (N = 521) n (%)
Histology    
   Non-squamous cell carcinoma 283 (85.0) 161 (85.6) 444 (85.2)
   Squamous cell carcinomaa 50 (15.0) 27 (14.4) 77 (14.8)
Disease stage at study entry    
   Stage IIIa 18 ( 5.4) 17 ( 9.0) 35 ( 6.7)
   Stage IIIb 65 (19.5) 38 (20.2) 103 (19.8)
   Stage IV 250 (74.1) 133 (70.7) 383 (73.5)
Karnofsky Index (KI)    
   KI ≥ 80% 207 (62.2) 116 (61.7) 323 (62.0)
   KI 70% 89 (26.7) 45 (23.9) 134 (25.7)
   KI 60% 27 ( 8.1) 18 ( 9.6) 45 ( 8.6)
   KI 50% 10 ( 3.0) 8 ( 4.3) 18 ( 3.5)
   Missing data 0 ( 0.0) 1 ( 0.5) 1 ( 0.2)
  1. N = total number of patients, n = number of patients
  2. a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma
\